Tenecteplase (TNK) Dosing for Acute Ischemic Stroke

Weight-based table per U.S. prescribing information for tenecteplase (TNKase) in adults with acute ischemic stroke. Confirm reconstitution and final concentration with the current package insert before drawing dose.

Body weight

Disclaimer: This tool is for educational support only. It does not verify eligibility for thrombolysis, substitute for the official prescribing information, or replace institutional protocols and clinician judgment.

Tenecteplase (TNKase) for acute ischemic stroke

For adults with acute ischemic stroke, U.S. labeling specifies a single intravenous bolus dose chosen from a weight-based table. The maximum recommended dose is 25 mg. Administration is described as a bolus given over approximately 5 seconds; treat as early as possible within the labeled time from symptom onset and follow hemodynamic monitoring recommendations in the full prescribing information.

Always use the current package insert and your pharmacy/clinical protocol for reconstitution, compatible fluids, and final concentration. This page assumes a 5 mg/mL concentration for translating the labeled dose (mg) to withdraw volume (mL), consistent with manufacturer AIS dosing references.

Weight-based dose table (adults, AIS)

Patient weight	Tenecteplase dose	Volume at 5 mg/mL
< 60 kg	15 mg	3 mL
≥ 60 to < 70 kg	17.5 mg	3.5 mL
≥ 70 to < 80 kg	20 mg	4 mL
≥ 80 to < 90 kg	22.5 mg	4.5 mL
≥ 90 kg	25 mg (maximum)	5 mL

Example

Adult weighing 75 kg:

Band: ≥ 70 to < 80 kg → 20 mg → 20 ÷ 5 = 4 mL (at 5 mg/mL)

What this calculator does not do

• It does not determine whether the patient meets inclusion/exclusion criteria for IV thrombolysis.
• It does not address extended time windows, wake-up stroke, advanced imaging selection, or tenecteplase before thrombectomy—follow AHA/ASA and local guidance.
• Research protocols sometimes use different mg/kg regimens; this tool reflects the labeled weight-band table, not trial-specific dosing.

What tenecteplase is and why dosing matters in stroke

Tenecteplase is a fibrin-specific recombinant tissue plasminogen activator engineered for longer plasma half-life and single-bolus administration compared with alteplase. In eligible adults with acute ischemic stroke (AIS), thrombolytic therapy aims to restore cerebral blood flow before irreversible infarction expands. Dosing must be accurate (under-dosing may reduce efficacy; overdosing increases hemorrhagic risk) and must always sit inside a broader pathway that includes neuroimaging, blood pressure control, coagulation assessment, contraindication review, and documentation.

The Tenecteplase (TNK) Dosing for Ischemic Stroke Calculator on CalcMD encodes the U.S. labeled weight-band table for tenecteplase in AIS. It reports the total milligram dose, the applicable weight stratum, and an approximate withdrawal volume when the prepared solution is at 5 mg/mL, consistent with manufacturer AIS dosing aids. It does not decide whether thrombolysis is appropriate or whether a given patient falls within the labeled treatment window.

Labeled dosing structure: weight bands, not a continuous mg/kg slide rule

For AIS, prescribing information individualizes dose by discrete body-weight ranges rather than a single continuous milligram-per-kilogram multiplier applied at every weight. The maximum recommended total dose is 25 mg. Typical labeled strata are:

Below 60 kg: 15 mg
60 kg up to (but not including) 70 kg: 17.5 mg
70 kg up to (but not including) 80 kg: 20 mg
80 kg up to (but not including) 90 kg: 22.5 mg
90 kg and above: 25 mg (capped maximum)

Boundary weights (for example, exactly 60.0 kg or 70.0 kg) must be read against the table’s inclusive/exclusive cutoffs exactly as written in the current package insert; the calculator follows the standard interpretation used in clinical dosing cards (e.g., 60 kg falls in the 60–70 kg band).

From milligrams to milliliters: why 5 mg/mL appears in the tool

Clinicians ultimately withdraw a volume from a vial after reconstitution (and any dilution steps required by institutional pharmacy policy and the official instructions). Manufacturer AIS materials commonly express bolus volume assuming a final concentration of 5 mg/mL for the solution used for the bolus. The CalcMD calculator therefore shows:

Total dose (mg) from the weight band
Volume (mL) = dose (mg) ÷ 5 mg/mL as a practical check (for example, 20 mg → 4 mL at that concentration)

If your site prepares tenecteplase to a different final concentration, you must rescale volume accordingly; the milligram dose from the table remains the anchor.

Administration characteristics emphasized in labeling and standard practice

Tenecteplase for AIS is given as an intravenous bolus, commonly described as approximately five seconds in product communications. Therapy should be initiated as early as feasible within the labeled time from symptom onset (institutions also apply guideline-based windows and imaging paradigms that may extend or narrow eligibility beyond a simple clock). During and after administration, blood pressure should be monitored and treated per protocol because hypertension worsens hemorrhagic complications.

Coagulation testing strategy depends on context. In selected patients without recent anticoagulant exposure, initiation may occur while labs are pending, with plans to adjust management if results reveal unacceptable risk; when INR or aPTT are markedly abnormal, closer monitoring and escalation pathways are required. These decisions are clinical, not outputs of a dose calculator.

Hemorrhage risk and systems-level safety

Like other thrombolytics, tenecteplase can cause serious or fatal bleeding. Risk rises with uncontrolled hypertension, recent surgery or invasive procedures, bleeding diathesis, concurrent antithrombotic drugs, and intracranial pathologies that predispose to hemorrhage. Active intracranial hemorrhage and other labeled contraindications must be excluded before bolus delivery.

Operational safeguards—two-provider checks of weight, dose, and vial, barcode verification, pre-printed order sets, and pharmacy oversight—reduce wrong-patient and wrong-dose errors. After treatment, teams should minimize arterial and venous punctures where compression is difficult, observe for neurologic change suggesting hemorrhagic transformation, and maintain clear communication with neurosurgery/interventional teams when escalation is needed.

How this calculator fits alongside guidelines and trials

Professional society guidelines for early AIS management evolve with trial evidence on imaging selection, extended windows, and thrombectomy pathways. Some research protocols have evaluated alternative tenecteplase dose strategies (for example, weight-based milligram-per-kilogram regimens in specific study populations). The CalcMD tool is intentionally aligned with the FDA-labeled weight-band schedule for product use in AIS, not with every investigational or off-label scheme.

When tenecteplase is considered as a bridge to mechanical thrombectomy or in transfer networks, local algorithms may add criteria (imaging core/penumbra estimates, collateral grades, time metrics). None of those inputs are computed here; the calculator answers a narrower, still critical question: Given an adult weight and the labeled AIS table, what is the prescribed total dose and the corresponding volume at 5 mg/mL?

Appropriate use, documentation, and limitations

Best use of the calculator assumes an up-to-date weight (actual body weight used for dosing per protocol), correct unit entry (kilograms versus pounds—CalcMD converts using standard factors), and confirmation against the current prescribing information and institutional monograph. Pediatric use, pregnancy, and severe renal or hepatic dysfunction may invoke additional scrutiny; the AIS indication and table addressed here target the adult labeling context.

Educational disclaimer: CalcMD does not provide medical advice. The calculator does not verify inclusion or exclusion criteria, imaging eligibility, blood pressure thresholds, anticoagulant or antiplatelet timing rules, or documentation requirements. Always follow governing protocols, pharmacy preparation instructions, and clinician judgment.

CalcMD.

Tenecteplase (TNK) Dosing for Ischemic Stroke Calculator

FDA-labeled weight-band tenecteplase (TNKase) dose for acute ischemic stroke: total mg, bolus mL at 5 mg/mL, administration and safety context. Educational; confirm with prescribing information.